| 纯度 | >92%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CST9L |
| Uniprot No | Q9H4G1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-147aa |
| 氨基酸序列 | MLGLPWKGGL SWALLLLLLG SQILLIYAWH FHEQRDCDEH NVMARYLPAT VEFAVHTFNQ QSKDYYAYRL GHILNSWKEQ VESKTVFSME LLLGRTRCGK FEDDIDNCHF QESTELNNTF TCFFTISTRP WMTQFSLLNK TCLEGFH |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CST9L重组蛋白的模拟参考文献示例(仅供参考，具体文献需通过数据库检索确认)：
---
1. **文献名称**: *Expression and Functional Analysis of Recombinant CST9L Protein in Tumor Suppression*
**作者**: Li X, et al.
**摘要**: 本研究通过大肠杆菌表达系统成功制备了重组CST9L蛋白，并验证其作为半胱氨酸蛋白酶抑制剂的活性。实验表明，CST9L重组蛋白可抑制肿瘤细胞迁移，提示其潜在抗肿瘤功能。
2. **文献名称**: *Purification and Characterization of CST9L Recombinant Protein in Epithelial Cells*
**作者**: Zhang Y, Wang T.
**摘要**: 文章报道了利用哺乳动物细胞系统表达CST9L重组蛋白的优化方法，通过亲和层析纯化获得高纯度蛋白，并证实其参与调控上皮细胞凋亡通路。
3. **文献名称**: *CST9L Recombinant Protein Modulates Cathepsin Activity in Neurodegenerative Models*
**作者**: Smith J, et al.
**摘要**: 研究利用重组CST9L蛋白探究其对神经细胞中组织蛋白酶活性的抑制作用，结果表明其可能通过调控蛋白酶活性缓解神经退行性病变模型中的细胞损伤。
---
**备注**：若实际文献检索结果有限，建议检查拼写(如是否为CST9L、cystatin-9类似物或相关家族蛋白)，或结合具体研究领域(如癌症、神经科学)扩展关键词。
CST9L (Cystatin-Related Protein 9-Like) is a member of the cystatin superfamily, known for its role as a cysteine protease inhibitor. This protein is structurally related to type 2 cystatins, which typically regulate proteolytic enzymes like cathepsins to maintain cellular homeostasis. CST9L is encoded by the CST9L gene and shares homology with CST9. though its functional profile remains less characterized compared to other cystatins. It is primarily expressed in epithelial tissues, including the skin, gastrointestinal tract, and reproductive organs, suggesting a tissue-specific regulatory function in protease activity.
Research indicates that CST9L may participate in immune modulation and antimicrobial defense by inhibiting proteases involved in pathogen invasion or inflammatory responses. Unlike its close relative CST6 (associated with tumor suppression and metastasis inhibition), CST9L’s biological significance is less defined but has been linked to epithelial barrier integrity and mucosal immunity. Studies in model organisms hint at its potential involvement in reproductive biology, though mechanistic insights are limited.
Recombinant CST9L protein is produced using expression systems like E. coli or mammalian cells to enable functional studies. Purification often involves affinity chromatography to ensure high purity and activity. Recombinant versions allow researchers to explore its biochemical properties, substrate specificity, and interactions with proteases or immune receptors. Current applications include in vitro assays to dissect its inhibitory kinetics, cell-based studies to evaluate its impact on protease-dependent pathways, and preclinical models to assess therapeutic potential in inflammatory or infectious diseases.
Despite progress, challenges persist in clarifying its physiological roles, structural dynamics, and disease associations. Ongoing research aims to elucidate its relevance in cancer, autoimmune disorders, and microbial infections, leveraging recombinant CST9L as a tool for drug discovery or diagnostic development.
×
